GlassScriptPhysician profile
Venkata S Golla
NPI 1821250325
$2,320.93
in general payments reported to CMS, 2019-2025
27 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.83 · 2020: $73.16 · 2021: $100 · 2022: $34.38 · 2023: $107 · 2024: $691 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046 · Education: $47.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.69 |
| Education | $47.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $238.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $202.90 | 2020-2023 | Xarelto |
| Amgen INC. | $192.21 | 2024-2025 | Tavneos, Aranesp, Parsabiv |
| Daiichi Sankyo INC. | $158.57 | 2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $156.19 | 2024-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $137.62 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $136.26 | 2025 | Tarpeyo |
| Travere Therapeutics, INC. | $111.35 | 2025 | Filspari |
| Glaxosmithkline, LLC. | $87.68 | 2024-2025 | Benlysta |
| Akebia Therapeutics INC | $85.87 | 2025 | Vafseo |
| Ardelyx, INC. | $84.56 | 2024-2025 | Ibsrela |
| Pfizer INC. | $80.26 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $77.86 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $68.94 | 2025 | Ozempic |
| Fresenius USA Marketing, INC. | $67.51 | 2024-2025 | Velphoro, Velphoro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $64.23 | 2025 | Veltassa |
| Viatris Specialty LLC | $62.02 | 2025 | Yupelri |
| Medtronic, INC. | $50.45 | 2021-2025 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $42.56 | 2025 | |
| Abiomed | $34.76 | 2024 | Impella |
| Indivior INC. | $30.98 | 2024 | |
| Philips North America LLC | $28.36 | 2023 | |
| Alexion Pharmaceuticals, INC. | $26.97 | 2025 | Ultomiris |
| Mylan Specialty L.P. | $25.68 | 2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.97 | 2025 | Jardiance |
| Shield Therapeutics INC | $24.65 | 2024 | |
| Recor Medical INC | $19.27 | 2025 | Paradise Ultrasound Renal Denervation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkata Golla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.